Form 8-K - Current report:
SEC Accession No. 0001438533-23-000006
Filing Date
2023-02-23
Accepted
2023-02-23 16:05:01
Documents
14
Period of Report
2023-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20230223.htm   iXBRL 8-K 43067
2 EX-99.1 aex991_2022q4x10xkearnings.htm EX-99.1 187220
6 GRAPHIC image.jpg GRAPHIC 8819
  Complete submission text file 0001438533-23-000006.txt   404764

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20230223.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20230223_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20230223_pre.xml EX-101.PRE 13044
8 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20230223_htm.xml XML 11268
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 23659561
SIC: 2834 Pharmaceutical Preparations